Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

PRAME gene expression profile in medulloblastoma.

Vulcani-Freitas TM, Saba-Silva N, Cappellano A, Cavalheiro S, Toledo SR.

Arq Neuropsiquiatr. 2011 Feb;69(1):9-12.

2.

ASPM gene expression in medulloblastoma.

Vulcani-Freitas TM, Saba-Silva N, Cappellano A, Cavalheiro S, Marie SK, Oba-Shinjo SM, Malheiros SM, de Toledo SR.

Childs Nerv Syst. 2011 Jan;27(1):71-4. doi: 10.1007/s00381-010-1252-5. Epub 2010 Aug 6.

PMID:
20694558
3.

Overexpressed TP73 induces apoptosis in medulloblastoma.

Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY.

BMC Cancer. 2007 Jul 12;7:127.

4.

Cancer-testis (CT) antigen expression in medulloblastoma.

Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK.

Cancer Immun. 2008 Apr 22;8:7.

5.

Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes.

Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, Riggins GJ.

Oncogene. 2003 Oct 23;22(48):7687-94.

PMID:
14576832
6.

Multidrug resistance gene expression in childhood medulloblastoma: correlation with clinical outcome and DNA ploidy in 29 patients.

Chou PM, Reyes-Mugica M, Barquin N, Yasuda T, Tan X, Tomita T.

Pediatr Neurosurg. 1995;23(6):283-91; discussion 291-2.

PMID:
8743996
7.

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M.

Clin Cancer Res. 2004 Jul 1;10(13):4307-13.

8.

PRAME gene expression in childhood acute lymphoblastic leukemia.

Steinbach D, Viehmann S, Zintl F, Gruhn B.

Cancer Genet Cytogenet. 2002 Oct 1;138(1):89-91.

PMID:
12419593
9.

Correlation of gamma-catenin expression with good prognosis in medulloblastomas.

Misaki K, Marukawa K, Hayashi Y, Fukusato T, Minamoto T, Hasegawa M, Yamashita J, Fujisawa H.

J Neurosurg. 2005 Mar;102(2 Suppl):197-206.

PMID:
16156230
10.

Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.

Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P.

Cancer Res. 2004 May 1;64(9):3103-11.

11.

Medulloblastoma: what is the role of molecular genetics?

Entz-Werle N, Carli ED, Ducassou S, Legrain M, Grill J, Dufour C.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1169-81. doi: 10.1586/14737140.8.7.1169. Review.

PMID:
18588461
12.

PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.

Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G.

Leuk Res. 2007 Mar;31(3):365-9. Epub 2006 Aug 17.

PMID:
16914202
13.

PRAME Expression and Its Clinical Relevance in Hodgkin's Lymphoma.

Ercolak V, Paydas S, Bagir E, Ergin M, Seydaoglu G, Celik H, Yavu B, Tanriverdi K, Gunaldi M, Afsar CU, Duman BB.

Acta Haematol. 2015;134(4):199-207.

PMID:
26044287
14.

Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B.

Cancer Genet Cytogenet. 2002 Mar;133(2):118-23.

PMID:
11943337
15.

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.

Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ.

J Clin Oncol. 2006 Apr 20;24(12):1924-31. Epub 2006 Mar 27.

PMID:
16567768
16.

C-kit expression and mutational analysis in medulloblastoma.

Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S.

Pediatr Dev Pathol. 2004 Sep-Oct;7(5):493-8. Epub 2004 Jul 30.

PMID:
15547773
17.

Prediction of central nervous system embryonal tumour outcome based on gene expression.

Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR.

Nature. 2002 Jan 24;415(6870):436-42.

PMID:
11807556
18.

Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.

Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ.

J Clin Oncol. 2004 Mar 15;22(6):984-93. Epub 2004 Feb 17.

PMID:
14970185
19.

Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.

Frühwald MC, O'Dorisio MS, Rush LJ, Reiter JL, Smiraglia DJ, Wenger G, Costello JF, White PS, Krahe R, Brodeur GM, Plass C.

J Med Genet. 2000 Jul;37(7):501-9.

20.

The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.

Santamaría C, Chillón MC, García-Sanz R, Balanzategui A, Sarasquete ME, Alcoceba M, Ramos F, Bernal T, Queizán JA, Peñarrubia MJ, Giraldo P, San Miguel JF, Gonzalez M.

Haematologica. 2008 Dec;93(12):1797-805. doi: 10.3324/haematol.13214. Epub 2008 Sep 24.

Supplemental Content

Support Center